🇺🇸 FDA
Pipeline program

sIPV+DTaP+HepA

sIPV-DTaP-HepA-2020

Approved mab active

Quick answer

sIPV+DTaP+HepA for Vaccination is a Approved program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Vaccination
Phase
Approved
Modality
mab
Status
active

Clinical trials